Ligand Q3 Adjusted EPS Beats at $2.67 as Revenue Jumps 71.5% to $149M
LGND sits 80% above its 52-week low of $175.89.
Summary
Ligand's Q3 adjusted EPS came in at $2.67 versus the $2.38 consensus, and revenue of $149.03 million blew past the $77.23 million analysts expected, up 71.5% year-over-year. The GAAP picture is a $28.49 million loss, or $1.43 per share, a swing from Q2's profit, but that reflects the accounting on the XOMA Royalty acquisition closed in July rather than operating weakness. Royalty revenue rose 51% to $70.3 million, and the company raised 2026 adjusted EPS guidance to $9, per the 8-K filed this morning. The stock sits near its 52-week high of $326.63 after gaining 68.6% this year, so the bar was high and the revenue beat clears it. Watch whether the raised guidance holds through Q4 as Filspari and the newly acquired royalty streams ramp.
At the time of this announcement, LGND was trading at $316.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $175.89 to $326.63. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.